UCANACT secures €800,000 in pre-seed funding led by LUMO Labs and Utrecht Holdings Seed Fund to develop brain-computer interface technology for people with motor impairments.
Utrecht-based neurotechnology startup UCANACT has raised €800,000 in pre-seed funding to advance its brain-computer interface (BCI) technology that translates brain signals into computer actions and speech. The investment is led by LUMO Labs and Utrecht Holdings Seed Fund. UCANACT's BCI system analyzes brain activity and enables users with severe motor impairments to communicate independently, with demonstrated 90% accuracy for yes/no commands. The technology works with both brain implants and wearable devices, incorporating personalized AI to minimize user training requirements.
Company Information
Company
UCANACT
Location
Utrecht, Utrecht, Netherlands
About
UCANACT is a Utrecht-based neurotechnology startup developing brain-computer interface (BCI) technology that translates brain signals directly into computer actions and speech. The company's device-agnostic system works with both brain implants and wearable devices, utilizing personalized AI to minimize user training. Their technology has achieved 90% accuracy for yes/no commands and over 90% for decoding individual words, with three ongoing clinical studies validating results. The solution aims to help people with severe motor impairments regain autonomy and communicate independently.
Fundz sees it the moment UCANACT raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
UtrechtInformation TechnologyBiotechnologySoftwareHealth CareArtificial IntelligenceMachine LearningHealth Diagnostics